Loading
A phase 1/2 trial of Trastuzumab, Osimertinib and Capecitabine in advanced solid tumours, run by DualityBio Inc., now recruiting.
A Study of DB-1310 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05785741 by DualityBio Inc., with 1000 participants planned, started 2023-08-17 and due to reach its primary completion in 2027-12-30. Interventions recorded: DB-1310, Trastuzumab, Osimertinib and capecitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Osimertinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/